Results 181-200 of 333 for 5 million speaker:Simon Harris
- Joint Oireachtas Committee on Future of Mental Health Care: Engagement with Minister for Health and Minister of State at the Department of Health (11 Jul 2018)
Simon Harris: ...tangible, real examples of what this means to people on the ground. On the issue of funding I have committed to the need to increase the budget next year and we have committed to adding €55 million. The Senator asked about equitable distribution and how to make sure each region or area is getting a fair share. I am due to visit Kilkenny this month and will meet the CHO...
- Written Answers — Department of Health: Hospital Waiting Lists Data (28 Jun 2018)
Simon Harris: Improving waiting times for hospital procedures is a key commitment in the Programme for Government and in 2018 €50 million was allocated to the NTPF to provide treatment for patients. The recently launched Inpatient/Day Case Action Plan outlines the combined impact of HSE and NTPF activity in 2018 to reduce the number of patients waiting for treatment to below 70,000 in 2018. This...
- Written Answers — Department of Health: Hospital Waiting Lists Data (12 Jun 2018)
Simon Harris: I propose to take Questions Nos. 896 and 924 together. Improving waiting times for hospital procedures is a key commitment in the Programme for Government and in 2018 €50 million was allocated to the NTPF to provide treatment for patients. The recently launched Inpatient/Day Case Action Plan outlines the combined impact of HSE and National Treatment Purchase Fund (NTPF) activity in...
- Written Answers — Department of Health: General Practitioner Contracts (25 Apr 2018)
Simon Harris: I propose to take Questions Nos. 144 and 145 together. Under the General Medical Services (GMS) contract, GPs are reimbursed for a range of services they provide to medical card and GP visit card holders. GPs are remunerated for these services primarily on a capitation basis, with a range of additional support payments and fees for specific items of service. GPs are also remunerated for...
- Ceisteanna - Questions - Priority Questions: Hospital Admissions (19 Apr 2018)
Simon Harris: ...investment we appropriately should make in general practice. Against a background of growing demand for unscheduled care and high acute hospital occupancy rates, the Government provided €30 million in 2017 and a further €40 million in 2018 for measures to increase acute hospital capacity and alleviate overcrowding in emergency departments. Almost 50% of this funding was...
- Written Answers — Department of Health: Psychological Services (19 Apr 2018)
Simon Harris: ...to address access to primary care-based counselling services for under 18s, the Government has prioritised investment in this area. The HSE's National Service Plan 2016 provided an additional €5 million for psychology for children with a focus on enhanced counselling interventions for children and adolescents. Recruitment of these posts, which includes a mix of psychologists and...
- Written Answers — Department of Health: General Practitioner Data (17 Apr 2018)
Simon Harris: ...supplementary out of hours fee is also payable for each patient on a GP's panel. The current capitation rates are set out as follows. GMS Scheme: Annual Capitation Rates Payable to Gps Age Male Female 0-5 €125 €125 6-15 €43.29 €43.79 16-44 €55.26 €90.37 45-64 €110.38 €121.29 65-69 €116.28 €129.72 70...
- Written Answers — Department of Health: General Practitioner Contracts (17 Apr 2018)
Simon Harris: .... Despite reductions to the payment rates of health contractors made under FEMPI legislation, the total fees paid to GPs under the GMS scheme have increased during this period from just over €472 million in 2009 to approximately €517 million in 2017. This increase in fees is largely due to significant developments and investment in GP services introduced in recent years,...
- Written Answers — Department of Health: Medicinal Products Availability (21 Feb 2018)
Simon Harris: ...efficiently and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic...
- Written Answers — Department of Health: Medicinal Products Availability (20 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Reimbursement (20 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Availability (20 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Availability (20 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Availability (20 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products (20 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Reimbursement (20 Feb 2018)
Simon Harris: ...effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Availability (15 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Availability (15 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medical Card Drugs Availability (14 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Topical Issue Debate: Drugs Payment Scheme Coverage (13 Feb 2018)
Simon Harris: ...continued access to the patches. I am concerned that I have heard many patients worried and upset about this and it is important that they hear how they can have their case reviewed. Lidocaine 5% medicated plasters are licensed to treat neuropathic pain from previous shingles infection, or post-herpetic neuralgia, PHN, in adults. They have been reimbursed in the community drugs schemes...